Amicus Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 517
- Market Cap
- $3.3B
- Website
- http://www.amicusrx.com
- Introduction
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Drug-drug Interaction Study
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT01380743
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- Biological: agalsidase
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT01218659
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT01196871
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 67
- Registration Number
- NCT00925301
A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT00875160
- Locations
- 🇺🇸
Comprehensive Phase One, Miramar, Florida, United States
🇬🇧Guy's Drug Research Unit, London, United Kingdom
A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients
- Conditions
- Gaucher DiseaseType 1 Gaucher DiseaseGaucher Disease, Type 1
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT00813865
Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT00688597
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00526071
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
- Conditions
- Glycogen Storage Disease Type IIPompe Disease
- Interventions
- Other: Observation
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2008-06-05
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00515398
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
- Conditions
- Gaucher DiseaseType 1 Gaucher DiseaseGaucher Disease, Type 1
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT00446550